Tech
Stories by Tim Boreham
Health & Biotech
Dr Boreham’s Crucible: A cure for the common cold? Why Firebrick Pharma might pass the sniff test
Health & Biotech
Dr Boreham’s Crucible: Does EBR have the ticker to tackle the charge cable conundrum?
Health & Biotech
Dr Boreham’s Crucible: Can fans of the ‘green whistle’ breathe easier as (if) Covid fades away?
Health & Biotech
Dr Boreham’s Crucible: With two new partners, can Imagion shake off Covid-interrupted syndrome?
Experts
Twenty-One of the Best: Tim Boreham’s Hot Stocks for 2022
Health & Biotech
Dr Boreham’s Crucible: Visoneering’s taking the longview on short-sightedness – and it’s starting to pay off
Health & Biotech
HealthKick Podcast: Life sciences expert on local medical innovations, tech leaders and sector opportunities
Health & Biotech
HealthKick Podcast: ASX biotech Dimerix gains momentum from involvement in multiple COVID-19 studies
Health & Biotech
Dr Boreham’s Crucible: Breaking down ASX aspirant Artrya’s AI heart disease warning system
Health & Biotech
Dr Boreham’s Crucible: Breaking down the post-COVID market opportunity for Uscom
Health & Biotech